MANTLE CELL LYMPHOMA

This study tested two different chemotherapy combinations, with or without the drug rituximab, for younger patients (age 65 or younger) newly diagnosed with mantle cell lymphoma. After initial treatment, patients received up to two years of maintenance therapy to help keep the ca…

This study tested a multi-step treatment approach for adults with previously untreated mantle cell lymphoma, a type of blood cancer. Patients received chemotherapy combined with a targeted drug (obinutuzumab), followed by a stem cell transplant using their own cells. After the tr…

This study tested a combination of four drugs (acalabrutinib, bendamustine, rituximab, and cytarabine) for people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The goal was to see if adding acalabrutinib to the standard treatment was safe and more effective a…

This study tested a new, more convenient schedule for radiation therapy given before CAR T-cell treatment. Ten adults with B-cell lymphoma that had returned or not responded to other treatments received radiation once a week for five weeks. The main goal was to see if this weekly…

This study tested a drug called zanubrutinib for people with several types of B-cell lymphoma who had to stop their previous treatments due to bad side effects. The main goal was to see if zanubrutinib caused fewer or less severe side effects for these patients. Researchers also …

This early-phase study tested the safety and best dose of a new drug called BGB-10188. It was given alone or combined with other cancer drugs to 97 patients with advanced blood cancers or solid tumors that had returned or stopped responding to prior treatments. The main goal was …

This study tested a new oral medication called pirtobrutinib for people with chronic lymphocytic leukemia or other B-cell lymphomas that had stopped responding to standard treatments. The main goals were to find a safe and effective dose and to see if the drug could shrink tumors…

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This study tested whether adding the drug bortezomib after a strong treatment regimen and a stem cell transplant could help people with newly diagnosed mantle cell lymphoma. The main goal was to see if this extra step could keep the cancer from coming back for a longer period. Re…

This study tested the safety of swapping out one drug (cyclophosphamide) for another (bendamustine) in the days following a bone marrow transplant. It involved 50 patients with various blood cancers who needed a transplant but lacked a perfectly matched donor. The goal was to see…

This study tested a less intense bone marrow transplant procedure for adults with various blood cancers who needed a transplant but did not have a fully matched donor. It used stem cells from a half-matched family member (like a parent, child, or sibling) after a milder pre-trans…

This study looked back at PET scan images from 200 patients with mantle cell lymphoma who were already part of a larger treatment trial. The goal was to see if information from these scans, taken at diagnosis and during treatment, could help doctors better predict how the disease…

This study created a patient registry to observe how newer, targeted cancer drugs work in everyday practice for people with mantle cell lymphoma. It followed 227 patients who had recently started one of these newer treatments to track their treatment patterns, how well the drugs …